Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Insulet Reports Second Quarter 2018 Revenue of $124.3 Million, Up 13% Year-Over-Year, and Gross Margin of 66%, Up 710 Basis Points
Full Year 2018 Expected Revenue Growth Revised to 18% to 21% Third Quarter Expected Revenue Growth of 19% to 24% BILLERICA, Mass. --(BUSINESS WIRE)--Aug. 2, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ®
View HTML
Toggle Summary Insulet Extends Partnership with Glooko in Europe to Optimise Diabetes Data Management
LONDON --(BUSINESS WIRE)--Jul. 12, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the global leader in  tubeless insulin pump  technology with its Omnipod ®  Insulin Management System (Omnipod System), today announced that it has partnered with Glooko ® , Inc.
View HTML
Toggle Summary Insulet to Announce Second Quarter 2018 Financial Results on August 2, 2018
BILLERICA, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the second quarter of 2018
View HTML
Toggle Summary Insulet Partners with the International Diabetes Federation Europe to Support Advocacy Activities Across the Continent
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--Jul. 9, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the global leader in  tubeless insulin pump  technology with its Omnipod ®  Insulin Management System (Omnipod System), today announced it has entered into a partnership with
View HTML
Toggle Summary Omnipod® Insulin Management System Now the Preferred Insulin Pump in British Columbia, Canada
Tubeless, Waterproof * Insulin Pump and Wireless, Handheld Personal Diabetes Manager Make Switching from Multiple Daily Injections to Pump Therapy Much Easier BILLERICA, Mass. & ONTARIO, Canada --(BUSINESS WIRE)--Jul. 3, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the
View HTML
Toggle Summary Insulet Assumes Direct Operations of its Omnipod® Insulin Management System Product Line in Europe
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--Jul. 2, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in  tubeless insulin pump  technology with its Omnipod ®  Insulin Management System (Omnipod System), today announced as of July 1 , it has assumed direct commercial
View HTML
Toggle Summary Insulet Presents Positive Clinical Trial Results for the Omnipod® Horizon™ Hybrid Closed-Loop System at the American Diabetes Association's 78th Scientific Sessions
Omnipod ® Horizon ™ System Significantly Improves Glycemic Control in Patients with Type 1 Diabetes BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 24, 2018-- Insulet Corporation  (NASDAQ:PODD) (Insulet or the Company), the leader in  tubeless insulin pump technology with its Omnipod ®  Insulin Management
View HTML
Toggle Summary Insulet to Unveil New Omnipod® DASH™ System and Present Innovative Research at the American Diabetes Association's 78th Scientific Sessions
DASH System Features Sleek, Color Touch-Screen Handheld Personal Diabetes Manager, Bluetooth-Enabled, Waterproof 1 , Tubeless Pump BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 19, 2018-- Insulet Corporation  (NASDAQ: PODD) (Insulet or the Company), the leader in  tubeless insulin pump technology with
View HTML
Toggle Summary Insulet’s Omnipod® DASH™ Insulin Management System Receives FDA 510(k) Clearance
DASH System Features Sleek, Color Touch-Screen Handheld Personal Diabetes Manager, Bluetooth-Enabled, Waterproof 1 , Tubeless Pump and Suite of User-Friendly Mobile Applications No-Cost Personal Diabetes Manager with Purchase of Pods BILLERICA, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary Insulet to Present at Upcoming Investor Conference
BILLERICA, Mass. --(BUSINESS WIRE)--May 29, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at the William Blair & Company 38 th Annual Growth Stock
View HTML
Toggle Summary Insulet Reports First Quarter 2018 Revenue of $123.6 Million, Up 21% Year-Over-Year, and Gross Margin of 61.4%, Up 300 Basis Points, Exceeding Expectations
Increases Full Year 2018 Expected Revenue Growth to 22% to 25% on Strength in Global Omnipod; Introduces Second Quarter Expected Revenue Growth of 18% to 22% BILLERICA, Mass. --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless
View HTML
Toggle Summary Insulet Achieves Key Milestones to Support its Transition to Direct Operations in Europe on July 1, 2018
High-Caliber Team in Place Throughout Key Geographies Partnerships Established with Experienced European Companies for Customer Care and Logistics BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 3, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin
View HTML
Toggle Summary Insulet Establishes Two Significant Commercial Partnerships to Support its European Expansion
BILLERICA, Mass. & LONDON --(BUSINESS WIRE)--May 1, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it has entered into partnerships with two
View HTML
Toggle Summary Insulet to Announce First Quarter 2018 Financial Results on May 3, 2018
BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 5, 2018-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the first quarter of 2018 on May
View HTML
Toggle Summary Insulet to Share Omnipod Clinical Data at Three Major European National Diabetes Congresses
Strong Presence at National Professional Diabetes Congresses in the UK , France and Germany Demonstrates Insulet’s Commitment to the European Diabetes Community BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 14, 2018-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), the leader in tubeless
View HTML